

Supplementary material

Exploratory analyses of patient preferences for atezolizumab subcutaneous versus intravenous from the IMscin002 study in patients with non-small cell lung cancer

Authors:

Dr Margarita Majem^a; Associate prof. Busyamas Chewaskulyong^b; Dr Zanete Zvirbule^c; Prof. Ki Hyeong Lee^d; Dr Ernesto Korbenfeld^e; Dr Jaroslaw Kolb-Sielecki^f; Dr Amparo Yovanna Castro Sanchez^g; Dr Alberto Bustillos^g; Dr Luis Herraiez-Baranda^g; Dr Xiaoyan Liu^h; Prof. Sang-We Kimⁱ; & Prof. Federico Cappuzzo^j

Affiliations:

^aDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí 08025 Barcelona, Spain

^bDivision of Medical Oncology, Department of Medicine, Chiang Mai University, Muang District, Chiang Mai 50200, Thailand

^cRiga Eastern Clinical University Hospital, Hipokrata Street 2, Riga, LV-1038, Latvia

^dDivision of Medical Oncology, Chungbuk National University Hospital, 776, 1Sunhwan-ro, Seowon-gu, Cheongju, 28644, Republic of Korea

^eHospital Británico de Buenos Aires, Perdriel 74, C1280AEB, Buenos Aires, Argentina

^fWarmian-Masurian Centre of Pulmonary Diseases, Jagiellońska 78, 10-357 Olsztyn, Poland

^gF. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland

^hGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

ⁱDepartment of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea

^jIRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy

Corresponding author:

Dr Margarita Majem, Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08025 Barcelona, Spain. Email: MMajem@santpau.cat

Table S1. Institutional review board information.

Site number	Investigator	EC/IRB name	EC/IRB approval date
350380	Sang-We Kim	Korea Central Ethics Committee	10 February 2022
350383	Ki Hyeong Lee		29 December 2021
350463	Milena Perez Mak	Comite de Etica do Hospital das Clinicas da FMUSP	16 September 2022
350467	Juliana de Menezes	CEP - Hospital Nossa Senhora da Conceição	07 December 2022
350468	Sergio De Azevedo	Comite de Etica do Hospital de Clinicas de Porto Alegre	17 November 2021
350470	Fabio Andre Franke	Comitê de Ética em Pesquisa, Universidade Regional do Noroeste do Estado do Rio Grande do Sul UNIJUÍ	05 September 2022
350521	Jaroslav Kolb-Sielecki	Kom. Bioet. przy Warm.-Mazur. Izbie Lek, ul. Zolnierska 16c, Olsztyn, Poland	01 February 2022
350522	Aleksandra Szczesna		
350527	Maria Juana Oramas Rodriguez	CEIC Hospital Universitario 12 de Octubre	02 December 2021
350528	Margarita Majem Tarruella		
350529	Dolores Isla Casado		
350530	Enriqueta Felip		
350531	Jon Zugazagoitia		
350532	M. Rosario Garcia Campelo		
350729	Monica Casalnuovo	Comite de Etica en Investigacion Clinica (CEIC), Buenos Aires, Argentina	14 October 2021
350730	Vanina Wainsztein		02 March 2022
350731	Ernesto Korbenfeld		27 December 2021
350837	Liza Villaruz	Advarra Headquarters, Columbia, USA	01 July 2022
350839	Apurv Agrawal		03 March 2022
350866	Jarkko Ahvonen	Pohjois-Pohjanmaan lääketieteellinen tutkimuseettinen toimikunta, Finland	04 January 2022
350867	Maria Silvoniemi		
350868	Sanna Livanainen		
350869	Antti Jekunen		
350887	Filippo De Marinis	Comitato Etico Degli IRCCS, Istituto Europeo di Oncologia, Milan, Italy	14 November 2021
350888	Michele Maio		16 November 2021
350890	Federico Cappuzzo		24 November 2021
350891	Federica Biello		17 December 2021
351339	Zanete Zvirbule	Ethics Committee, Pauls Stradins Clinical University Hospital, Latvia	22 February 2022
351340	Aija Gerina-Berzina		
351392	Luis Corrales Rodríguez	Comite Etico Cientifico, UCIMED, San José, Costa Rica	25 February 2022
351393	Adrián Guzman Ramirez		10 March 2022
351404	Noman Rafique	Advarra Headquarters, Columbia, USA	22 October 2021
351716	Francisco Orlandi	Comite de Etica, Servicio de Salud Metropolitano Oriente, Santiago, Chile	05 April 2022
351951	Stephanie Brule	Ontario Cancer Research Ethics Board, Barrie, Ontario, Canada	20 April 2022
351952	Robert El-Maraghi		19 April 2022
351953	Silvana Spadafora	Group Health Centre/Sault Area Hospital REB, Ontario, Canada	18 January 2022

352684	Alison Savage	Southern Oregon IRB, Medford, USA	24 February 2022
--------	---------------	-----------------------------------	------------------

EC ethics committee; IRB institutional review board


Table S2. Categorization of quartiles.

Quartile	Age, years	BMI	Mean injection duration, minutes^a	Cumulative number of injections administered per center^b
1	≤60	≤23	≤6.0	≥3–≤6
2	>60–≤67	>23–≤26	>6.0–≤7.0	>6–≤17
3	>67–≤74	>26–≤29.5	>7.0–≤8.4	>17–≤47
4	>74	>29.5	>8.4	>47–≤164

^aCycles 1–6. ^bPrior to questionnaire completion for each patient.

BMI body mass index.

Figure S1. IMscin002 study design.



^aPD-L1 expression assessed by local or central laboratory by VENTANA PD-L1 (SP263) or Dako PD-L1 IHC 22C3 pharmDx assay. ^bBased on a 70% preference rate with ±8% precision for the 95% CI and 28% missing questionnaire response rate. ^cat Cycle 6 Day 1 or after at least two consecutive administrations of each treatment in case of treatment discontinuation before Cycle 6 Day 1.

Atezo atezolizumab, *C* cycle, *CI* confidence interval, *D* day, *ECOG PS* Eastern Cooperative Oncology Group Performance Score, *IV* intravenous, *LOCB* loss of clinical benefit, *NSCLC* non-small cell lung cancer, *PD-L1* programmed-death-ligand 1, *Q3W* every 3 weeks, *R* randomization, *SC* subcutaneous.